false
Catalog
2023 World Conference on Lung Cancer (Posters)
EP13.07. Exploring Outcomes in Second-line Therapy ...
EP13.07. Exploring Outcomes in Second-line Therapy for Small Cell Lung Cancer with Brain Metastases: Lurbinectedin vs Others - PDF(Abstract)
Back to course
Pdf Summary
This presentation at the WCLC 2023 conference focused on the outcomes of second-line therapy for small cell lung cancer (SCLC) patients with brain metastases. Lurbinectedin was compared to other treatments such as topotecan, irinotecan, ipilumimab, and nivolumab. The study included 82 patients from the Inova Schar Cancer Institute, and data was collected from electronic health records (EHR) and manual chart reviews. <br /><br />The results showed that patients with brain metastases who received lurbinectedin stayed on treatment longer compared to those who received other second-line treatments. The median progression-free survival (PFS) for the lurbinectedin cohort was 150 days. Irinotecan and ipilimumab/nivolumab were also used in some patients, with a treatment duration of 71 and 122 days, respectively. No patient with brain metastases received nivolumab alone. <br /><br />The study suggests that patients with brain metastases from SCLC have a poor prognosis, but lurbinectedin may provide a longer treatment duration compared to the previous standard treatment, topotecan. Further research is needed to explore the role of other therapies such as irinotecan. The authors also highlight the value of using EHR data for selecting patients with refractory or progressive SCLC with brain metastases. Future studies are planned to identify the effects of survival between lurbinectedin, topotecan, and irinotecan in these patients.
Asset Subtitle
Faran Polani
Meta Tag
Speaker
Faran Polani
Topic
SCLC & Neuroendocrine Tumors: Relapse & Salvage Therapy
Keywords
WCLC 2023 conference
second-line therapy
small cell lung cancer
SCLC
brain metastases
lurbinectedin
topotecan
irinotecan
ipilumimab
nivolumab
×
Please select your language
1
English